Evaluation of antidiabetic effect of total calystegines extracted from Hyoscyamus albus

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 337-344

  Bourebaba, Lynda ^a   Saci, Souaad ^a   Touguit, Damia ^a   Gali, Lynda ^a   Terkmane, Schahinez ^a   Oukil, Naima ^a   Bedjou, Fatiha ^a  

^a UNIVERSITY OF BEJAIA   (Algeria)

Author keywords

Calystegines; Diabetes; Hyoscyamus albus L.; Hyperglycemia; Streptozotocine; Toxicity

Indexed keywords

ALKALOID; CALYSTEGINE A3; CALYSTEGINE A5; CALYSTEGINE A5 GLYCOSIDE; CALYSTEGINE B1; CALYSTEGINE B2; CALYSTEGINE B4; CALYSTEGINE DERIVATIVE; CALYSTEGINE N1; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; GLYCOSIDASE; HIGH DENSITY LIPOPROTEIN; HYOSCYAMUS EXTRACT; IMINOSUGAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CALYSTEGIN; LIPID; STREPTOZOCIN; TROPANE DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RETENTION; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYOSCYAMUS ALBUS; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN RELEASE; KIDNEY PARENCHYMA; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PLANT SEED; PRIORITY JOURNAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THERAPY EFFECT; TREATMENT DURATION; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRINKING BEHAVIOR; DRUG EFFECTS; FEEDING BEHAVIOR; GLUCOSE TOLERANCE TEST; HYOSCYAMUS; ISOLATION AND PURIFICATION; KIDNEY; LIVER; ORAL DRUG ADMINISTRATION; PANCREAS; PATHOLOGY; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRINKING BEHAVIOR; FEEDING BEHAVIOR; FEMALE; GLUCOSE TOLERANCE TEST; HYOSCYAMUS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; LIPIDS; LIVER; MALE; MICE; PANCREAS; SEEDS; STREPTOZOCIN; TOXICITY TESTS, ACUTE; TROPANES;

EID: 84969567719     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.05.011     Document Type: Article

References (29)

1. Arulselvan P., Abdoul Ghofar H.A., Karthivashan G., Abdul Halim M.F., Abdul Ghafar M.S., Fakurazi S. Antidiabetic therapeutics from natural. source: a systematic review. Biomed. Prev. Nutr. 2014, 4:607-617.
2. Asano N., Kato A., Kizu H., Matsui K., Watson A.A., Nash R.J. Calystegine B 4, a novel trehalase inhibitor from Scopolia japonica. Carbohydr. Res. 1996, 293:195-204.
3. Asano N., Kato A., Miyauchi M., Kizu H., Tomimori T., Matsui K., NASH R.J., Molyneux R.J. Specific a-galactosidase inhibitors, N methylcalystegines Structure/activity relationships of calystegines from Lycium chinense. Eur. J. Biochem. 1997, 248:296-303.
4. Asano N., Nash R., Molyneux C., Fleet G. Sugar-mimic glycosidase inhibitors: natura occurrence, biological activity and prospects for therapeutic application. Tetrahedron 2000, 11:1645-1680.
5. Barrett K., Brooks H., Boitano S., Barman S. Ganong's Review of Medical Physiology 2010, 727. McGraw-Hill Medical. twenty-third edition.
6. Bekkouche K., Daali Y., Cherkaoui S., Veuthey J.L., Christen P. Calystegine distribution in some solanaceous species. Phytochemistry 2001, 58:455-462.
7. Guyton A.C., Hall J.E. Textbook of Medical Physiology 2006, 1152. Elsevier Saunder, Pennsylvania. eleventh edition.
8. Heo S.J., Hwang J.W., Choi J.I., Han J.S., Kim H.J., Jeon Y.J. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur. J. Pharmacol. 2009, 615:252-256.
9. Howard B.V., Schneiderman N., Falkner B., Haffner S.M., Laws A. Insulin, health behaviors, and lipid metabolism. Metabolism 1993, 42:25-35.
10. Jakobsen P., Lundbeck J.M., Kristiansen M., Breinholt J., Demuth H., Pawlas J., Candela M.P., Andersen B., Westergaard N., Lundgren K., Asano N. Iminosugars: potential inhibitors of liver glycogen phosphorylase. Bioorg. Med. Chem. 2001, 9:733-744.
11. Kamesawara B.R., Giri R., Kesavulu M.M., Apparao C.H. Effect of oral administration of bark extracts of Pterocarpus santalinus L. on blood glucose level in experimental animals. J. Ethnopharmacol. 2000, 74:69-74.
12. Kuriyama C., Kamiyama O., Ikeda K., Sanae F., Kato A., Adachi I., Imahori T., Takahata H., Okamoto T., Asano N. In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered suger mimics and their evaluation in cell cultures. Bioorg. Med. Chem. 2008, 19:7330-7336.
13. 2 in potato. J. Chromatogr. A 2008, 1181:137-144.
14. Lee B., Eskandari R., Jones K., Ravinder Reddy K., Quezada-Calvillo R., Nichols B.L., Rose D.R., Hamaker B.R., Pinto B.M. Modulation of starch digestion for slow glucose release through toggling of activities of mucosal α-glucosidases. J. Biol. Chem. 2012, 287:31929-31938.
15. Lee S.H., Park M.H., Heo S.J., Kang S.M., Ko S.C., Han J.S., Jeon Y.J. Dieckol isolated from Ecklonia cava inhibits α-glucosidase and α-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice. Food Chem. Toxicol. 2010, 48:2633-2637.
16. Martinez-Montero S., Fernández S., Sanghvi Y.S., Chattopadhyaya J., Ganesan M., Ramesh N.G., Gotor V., Ferrero M. Design and divergent synthesis of aza nucleosides from a chiral imino sugar. J. Org. Chem. 2012, 77:4671-4678.
17. Molyneux R.J., Lee S.T., Gardner D.R., Panter K.E., James L.F. Phytochemicals: the good, the bad and the ugly?. Phytochemistry 2007, 68:2973-2985.
18. Nejadhabibvash F., Rahmani F., Heidari R., Jamei R. Assessment of genetic diversity among Hyoscyamus genotypes based on ISSR markers. Int. J. Agric. Crop Sci. 2012, 4:1300-1306.
19. OECD OECD Guidelines for Testing of Chemicals: Guideline 423: Acute Oral Toxicity 2001, Toxic-Class Method Office of Economic and Community Development, Paris.
20. Okon U.A., Owo D.U., Udokang N.E., Udobang J.A., Ekpenyong C.E. Oral administration of aqueous leaf extract of Ocimum gratissimum ameliorates polyphagia, polydipsia and weight loss in streptozotocin-induced diabetic rats. Am. J. Med. Med. Sci. 2012, 2:45-49.
21. Onda K., Shiraki R., Ogiyama T., Yokoyama K., Momose K., Katayama N., Orita M., Yamaguchi T., Furutani M., Hamada N., Takeuchi M., Okada M., Ohta M., Tsukamoto S. Design, synthesis, and pharmacological evaluation of N bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors. Bioorg. Med. Chem. 2008, 16:10001-10012.
22. Oniki Y., Kato T., Irie H., Mizuta H., Takagi K. Diabetes with hyperlipidemia: a risk factor for developing joint contractures secondary to immobility in rat knee joints?. J. Orthop. Sci. 2005, 10:221-226.
23. Priscilla D.H., Roy D., Suresh A., Kumar V., Thirumurugan K. Naringenin inhibits a-glucosidase activity: a promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats. Chem. Biol. Interact. 2014, 210:77-85.
24. Stegelmeier B.L., Molyneux R.J., Asano N., Watson A.A., Nash R.J. The comparative pathology of the glycosidase inhibitors swainsonine, castanospermine, and calystegines A3, B2, and C1 in mice. Toxicol. Pathol. 2008, 36:651-659.
25. Van Dijk J.W., Manders R.J.F., Hartgens F., Stehouwer C.D., Praet S.F.E., Van Loon L.J.C. Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients. Diabetes Res. Clin. Pract. 2001, 93:31-37.
26. Watson A., Fleet G., Asano N., Molyneux R., Nash R. Polyhydroxylated alkaloids: natural occurrence and therapeutic applications. Phytochemistry 2001, 56:265-295.
27. Yin H., Miao J., Zhang Y. Protective effect of β-casomorphin-7 on type 1 diabetes rats induced with streptozotocin. Peptides 2010, 31:1725-1729.
28. Zhang L., Yang J., Chen X., Zan K., Wen X., Chen H., Wang K., Lai M. Antidiabetic and antioxidant effects of extracts from Potentilla discolor Bunge on diabetic rats induced by high fat diet and streptozotocin. J. Ethnopharmacol. 2010, 132:518-524.
29. Zhou X., Zhang W., Liu X., Zhang W., Li Y. Interrelationship between diabetes and periodontitis: role of hyperlipidemia. Arch. Oral Biol. 2015, 60:667-674.